Effectiveness of Antidiabetic Treatment Applied in Childhood Obesity

HÜMEYRA ACIKAN

Status and phase: Completed; Phase 4

Conditions: Insulin Resistance; Childhood Obesity

Treatments: Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT06266598

EU-TF-HA-01

Details and patient eligibility

About

In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.

Enrollment: 52 patients

Sex: All

Ages: 9 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

inclusion criteria:

• Body mass index (BMI) > 95th percentile
• Having insulin resistance
• Having a family history of Type 2 diabetes mellitus (T2DM)

exclusion criteria;

• Alcohol consumption and smoking
• Having T1DM and T2DM
• History of drug use

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

52 participants in 1 patient group

obesity

Other group

Description:

Children with obesity were recommended to have a diet appropriate for their age and gender and exercise at least 3 days a week for at least 60 minutes each time. All obese children under the age of 14 were started on metformin treatment at 1000 mg (500 mgx2) per day, and children over this age were started on metformin treatment at the adult dose of 2000 mg (1000 mgx2) per day.

Treatment:

Drug: Metformin